Paul G. Allen Frontiers Group [to 1 Jun 2019]
No new digest content identified.

BMGF – Gates Foundation [to 1 Jun 2019]
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 1 Jun 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 1 Jun 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 1 Jun 2019]
29 May 2019
CEPI partners with Brighton Collaboration to support safety assessment of vaccine candidates
The Safety Platform for Emergency vACcines (SPEAC) Project will harness the expertise of the Brighton Collaboration to help assess the safety of various CEPI-funded vaccine candidates undergoing clinical trials.

Clinton Health Access Initiative, Inc. (CHAI) [to 1 Jun 2019]
No new digest content identified.

EDCTP [to 1 Jun 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 1 Jun 2019]
No new digest content identified.

European Medicines Agency [to 1 Jun 2019]
News and press releases
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-29 May 2019
[No vaccine act

European Vaccine Initiative [to 1 Jun 2019]
No new digest content identified.

FDA [to 1 Jun 2019]
No new digest content identified.

Fondation Merieux [to 1 Jun 2019]
6th Annual Meeting of the Global Task Force on Cholera Control (GTFCC)
June 3 – 4, 2019 – Les Pensières Center for Global Health, Veyrier du Lac (France)

Gavi [to 1 Jun 2019]
31 May 2019
Immunisation as a catalyst for women’s health, education, and economic empowerment
2019 Grassroots advocates and world leaders will gather in Vancouver, Canada, from 3-6 June for the Women Deliver conference to explore solutions to achieve a more gender equal world under the theme “Power. Progress. Change.” The meeting will be the world’s largest conference on gender equality and the health, rights, and wellbeing of girls and women. As a gender equal health intervention, immunisation plays a key role in keeping girls, adolescents and women healthy

Kingdom of Norway contributes NOK 600 million to IFFIm
29 May 2019

Major cholera vaccination campaign begins in North Kivu in the Democratic Republic of the Congo
27 May 2019
[See DRC Ebola/Cholera above for detail]

GHIT Fund [to 1 Jun 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 1 Jun 2019]
No new digest content identified.

Hilleman Laboratories [to 1 Jun 2019]
No new digest content identified.

Human Vaccines Project [to 1 Jun 2019]
No new digest content identified.

IAVI [to 1 Jun 2019]
No new digest content identified.


29 May 2019
Kingdom of Norway contributes NOK 600 million to IFFIm
New donation will back Vaccine Bonds to fund CEPI’s fight against deadly diseases.
Geneva, 29 May 2019 – The Kingdom of Norway has agreed to donate NOK 600 million to the International Finance Facility for Immunisation (IFFIm). The donation is intended to support the Coalition for Epidemic Preparedness Innovation (CEPI). In a novel arrangement approved by Gavi, the Vaccine Alliance, IFFIm is planning to issue bonds on international capital markets, backed by the donation from Norway, which hosts CEPI…

IFRC [to 1 Jun 2019]
Selected Press Releases, Announcements
Media Advisory: Women Deliver Conference: Gender inequality in humanitarian crises, deadly gender divide in Ebola
Vancouver/Geneva, 31 May 2019 – The global head of the world’s largest humanitarian network will highlight the deadly consequences of gender inequality in the wake of disasters and conflicts, during a high-profile plenary session at the Women Deliver C …
31 May 2019

Bosnia and Herzegovina
Migrants in Bosnia and Herzegovina dying while seeking safety
Thousands of people trapped in Bosnia and Herzegovina desperately need humanitarian assistance and some are dying while trying to find shelter, says the International Federation of Red Cross and Red Crescent Societies (IFRC).
30 May 2019

Americas, Argentina
Major humanitarian conference to explore regional crises, migration
Buenos Aires/Panama/Geneva, 17 May 2018 – Red Cross leaders from across the Americas and around the world are gathering in Buenos Aires from 21-

IVAC [to 1 Jun 2019]
No new digest content identified.

IVI [to 1 Jun 2019]
IVI News & Announcements
New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand
30 May 2019, SEOUL, South Korea – The International Vaccine Institute (IVI) and Australia’s Murdoch Children’s Research Institute (MCRI) will coordinate a global push to free the world of Group A Streptococcus (Strep A), the contagious bacteria that kills half a million people every year and is developing resistance to antibiotics.
The British biomedical research foundation, the Wellcome Trust, has granted $2.25 million to IVI and MCRI to coordinate world efforts to develop a vaccine against Strep A and find manufacturers…

IVI´s Board of Trustees welcomes new members at annual meeting
24 May 2019, SEOUL, Korea — The International Vaccine Institute (IVI) held its first face-to-face meeting of the Board of Trustees (BOT) for 2019 in Seoul, Korea on May 23-24. In addition to reviewing IVI’s achievements and activities of the past year, the Board discussed and delineated this year’s plans for further accelerating IVI’s growing impact on global health.
The meeting brought together 16 members or designees of the Board from around the globe, including Board Chairman Mr. George Bickerstaff, the Managing Director of M.M. Dillon & Co.; Dr. Jerome Kim, Director General of IVI; and representatives from IVI’s signatory countries. The Board also welcomed three new members:
Dr. Catharina Maijgren Steffensson, representing Sweden on the BOT, is currently the Associate Director/Medical Director Nordics at Sarepta Therapeutics. She has a solid background in gene therapy & HIV research and has previously worked at the Swedish International Development Agency (Sida) and Gilead.
Prof. Ziad Ahmed A. Memish, is currently a Professor at the College of Medicine, AlFaisal University; Senior Consultant, Infectious Diseases in the Department of Medicine and Director of the Research Department at Prince Mohamed Bin Abdulaziz Hospital in Saudi Arabia, and Adjunct Professor in the Hubert Department of Global Health Rollins School of Public Health, Emory University in the U.S. He has served as the Deputy Minister of Health for Public Health, with the Saudi Ministry of Health, and served on many national, regional and international boards including: Chairman of the Board of Directors of the Saudi Center for Disease Control and Prevention, and Member of the Executive Board of WHO and the Executive Council of International Society of Infectious Diseases.
  Dr. Anthony Ford-Hutchinson is currently a Board Member or Scientific Advisor to multiple startup companies, including the position of CSO of Rbonova Inc, as well as not for profit organizations, the Hepatitis B Foundation, SAGE Bionetworks, the Wellcome Trust, CARB-X and CEPI. He has over 40 years of experience in pharmaceuticals, including an extensive tenure at Merck & Co with positions including Executive Vice President of Basic Research and Senior Vice President of Vaccine R&D…

JEE Alliance [to 1 Jun 2019]
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 1 Jun 2019]
Selected News; Project Updates, Reports
A day treating wounded in Yemen’s Al Salakhana hospital
Project Update 30 May 2019

DRC Ebola outbreaks
Crisis update – May 2019
Crisis Update 30 May 2019

MSF expands efforts to control dengue epidemic in northern Honduras
Project Update 29 May 2019

Bringing healthcare to places where no health posts exist
Project Update 27 May 2019

NIH [to 1 Jun 2019]
May 29, 2019
Experimental drug completely effective against Nipah virus infection in monkeys
— Nipah virus can cause neurological and respiratory disease; the mortality rate is about 70%.

The Human Microbiome Project expands the toolbox for studying host and microbiome interactions
May 29, 2019 — New studies provide a framework for future studies of the role of the microbiome in health and disease.

PATH [to 1 Jun 2019]
May 30, 2019 by PATH
New diagnostic will help propel development of improved malaria tests and support surveillance
Seattle, WA, and Logan, UT, May 30, 2019—PATH and Quansys Biosciences, Inc. have announced the launch of a new diagnostic tool designed to help researchers develop more sensitive and reliable malaria rapid diagnostic tests (RDTs) and to support public health surveillance. The Q-Plex™ Human Malaria Array (5-Plex) is a quantitative immunoassay that simultaneously measures multiple malaria antigens.
With almost half of the world’s population at risk for malaria and more than 200 million cases annually, the disease is a public health priority. Accurate diagnostics are critical to both disease management and public health surveillance. RDTs are a critical tool in malaria case management, particularly in remote settings, providing access to prompt diagnosis…

Sabin Vaccine Institute [to 1 Jun 2019]
No new digest content identified.

UNAIDS [to 1 Jun 2019]
Selected Press Releases/Reports/Statements
31 May 2019
The little-known links between cervical cancer and HIV

29 May 2019
Voluntary medical male circumcision accelerating in Malawi

UNICEF [to 1 Jun 2019]
Selected Statements, Press Releases, Reports
Joint statement: 1 UN for family leave and childcare

UNICEF Executive Director Henrietta Fore gives remarks during the Third International Conference on Safe Schools
As delivered

Press release
Attack in Taiz leaves 7 children dead, brings total child casualties in Yemen to 27 in just over 10 days
Statement by UNICEF Executive Director Henrietta Fore

Vaccine Confidence Project [to 1 Jun 2019]
Posted on 28 May 2019
Article pick of the Week: How the anti-vaccine movement crept into the GOP mainstream
Published in POLITICO    27 May 2019 By Arthur Allen
The anti-vaccine movement, which swelled with discredited theories that blamed vaccines for autism and other ills, has morphed and grown into a libertarian political rebellion that is drawing in state…

Vaccine Education Center – Children’s Hospital of Philadelphia [to 1 Jun 2019]
No new digest content identified.

Wellcome Trust [to 1 Jun 2019]
News | 31 May 2019
Wellcome updates open access policy to align with cOAlition S
Following a large consultation, we have updated our open access (OA) policy so it now aligns with Plan S. The changes will apply from 1 January 2021.

The Wistar Institute [to 1 Jun 2019]
No new digest content identified.

World Organisation for Animal Health (OIE) [to 1 Jun 2019]
No new digest content identified.



BIO [to 1 Jun 2019]
May 31 2019
BIO Releases 5th Annual Emerging Therapeutic Company Trend Report Showing Record Year for Venture Capital Funding
Washington, D.C. (May 31, 2019) – Today, the Biotechnology Innovation Organization (BIO) released the 2019 Emerging Therapeutic Company Trend Report, highlighting ten years (2009-2018) of biotechnology funding and deal making across five areas: venture capital, Initial Public Offerings (IPOs), follow-on public offerings, licensing, and acquisitions. The report also contains a 2019 snapshot of the industry’s clinical pipeline to highlight the significant contribution of emerging companies.

May 29 2019
BIO Honors Dr. Emil D. Kakkis with 2019 Henri A. Termeer Biotechnology Visionary Award
BIO announces the winner of this year’s Henri A. Termeer Biotechnology Visionary Award: Emil D. Kakkis, MD, PhD, President and Chief Executive Officer, Ultragenyx (NASDAQ: RARE) and Founder, EveryLife Foundation for Rare Diseases. The award, which will be presented to Dr. Kakkis on June 5 during the BIO 2019 International Convention keynote session, recognizes Dr. Kakkis’ transformative work to accelerate research and development of novel treatments for rare diseases.

DCVMN – Developing Country Vaccine Manufacturers Network [to 1 Jun 2019]
LG Chem received a $33.4 million grant from the Bill & Melinda Gates Foundation to develop a 6-in-1 combination vaccine to prevent childhood diseases

IFPMA [to 1 Jun 2019]
No new digest content identified.

PhRMA [to 1 Jun 2019]
No new digest content identified.